Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
-
BUSINESS Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up
December 25, 2020
-
BUSINESS 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally
December 24, 2020
-
ACADEMIA Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
-
REGULATORY Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
-
BUSINESS Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing
December 23, 2020
-
BUSINESS Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections
December 23, 2020
-
REGULATORY Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
-
ORGANIZATION 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit
December 21, 2020
-
REGULATORY Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget
December 21, 2020
-
BUSINESS Decision on Pfizer Vaccine Unlikely to Come before Japan Data Submission Slated by February
December 21, 2020
-
BUSINESS Pfizer/BioNTech’s COVID-19 Vaccine Filed in Japan, Exceptional OK Eyed
December 18, 2020
-
BUSINESS 5%-Plus Discrepancy Threshold for Off-Year Re-Pricing Draws Fire from Pharma, Wholesalers
December 18, 2020
-
REGULATORY Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
-
REGULATORY Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
-
REGULATORY Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
-
BUSINESS UCB Japan to Independently Market New Products; Stand-Alone E Keppra Sales “Going Smoothly”: President
December 16, 2020
-
REGULATORY Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
December 15, 2020
-
BUSINESS Forxiga Filed for Chronic Kidney Disease in Japan: AZ
December 15, 2020
-
BUSINESS 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…